[go: up one dir, main page]

CY1117886T1 - Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα - Google Patents

Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα

Info

Publication number
CY1117886T1
CY1117886T1 CY20161100779T CY161100779T CY1117886T1 CY 1117886 T1 CY1117886 T1 CY 1117886T1 CY 20161100779 T CY20161100779 T CY 20161100779T CY 161100779 T CY161100779 T CY 161100779T CY 1117886 T1 CY1117886 T1 CY 1117886T1
Authority
CY
Cyprus
Prior art keywords
naphthalenyl
pyrazol
oxy
ethyl
methyl
Prior art date
Application number
CY20161100779T
Other languages
English (en)
Inventor
Maimó Ramón Berenguer
Rupérez Jorge Medrano
Buchholz Jordi Benet
Fernandez Laura Puig
Puxeu Laia Pellejà
Original Assignee
Laboratorios Del Dr. Esteve, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10382025A external-priority patent/EP2361904A1/en
Priority claimed from EP10382226A external-priority patent/EP2426112A1/en
Application filed by Laboratorios Del Dr. Esteve, S.A. filed Critical Laboratorios Del Dr. Esteve, S.A.
Publication of CY1117886T1 publication Critical patent/CY1117886T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε πολύμορφα και επιδιαλυτώματα του υδροχλωρικού άλατος της 4-[2-[[5-μεθυλ- 1-(2-ναφθαλενυλ)-1Η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολίνης(Ρ027), σε διεργασίες για την παρασκευή τους και σε φαρμακευτικές συνθέσεις που τα περιέχουν.
CY20161100779T 2010-02-04 2016-08-08 Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα CY1117886T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP10382025A EP2361904A1 (en) 2010-02-04 2010-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
EP10382226A EP2426112A1 (en) 2010-08-09 2010-08-09 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
EP11702056.0A EP2531177B8 (en) 2010-02-04 2011-02-04 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates
PCT/EP2011/051630 WO2011095579A1 (en) 2010-02-04 2011-02-04 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates

Publications (1)

Publication Number Publication Date
CY1117886T1 true CY1117886T1 (el) 2017-05-17

Family

ID=43897079

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100779T CY1117886T1 (el) 2010-02-04 2016-08-08 Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα

Country Status (32)

Country Link
US (2) US9051275B2 (el)
EP (1) EP2531177B8 (el)
JP (1) JP5894086B2 (el)
KR (2) KR20120123532A (el)
CN (1) CN102753155B (el)
AR (1) AR080133A1 (el)
AU (1) AU2011212476B2 (el)
BR (1) BR112012018958A8 (el)
CA (1) CA2788024C (el)
CO (1) CO6592093A2 (el)
CY (1) CY1117886T1 (el)
DK (1) DK2531177T3 (el)
EC (1) ECSP12012039A (el)
ES (1) ES2586212T3 (el)
HR (1) HRP20160937T1 (el)
HU (1) HUE029738T2 (el)
IL (1) IL221277A (el)
MA (1) MA34047B1 (el)
ME (1) ME02483B (el)
MX (1) MX339193B (el)
NZ (1) NZ601316A (el)
PH (1) PH12012501510A1 (el)
PL (1) PL2531177T3 (el)
PT (1) PT2531177T (el)
RS (1) RS55046B1 (el)
RU (1) RU2560150C2 (el)
SG (2) SG10201500832PA (el)
SI (1) SI2531177T1 (el)
SM (1) SMT201600264B (el)
TN (1) TN2012000347A1 (el)
TW (1) TWI568729B (el)
WO (1) WO2011095579A1 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP3082782A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
CA2933057A1 (en) 2013-12-17 2015-06-25 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and sigma receptor ligands combinations
JP7094231B2 (ja) 2016-06-06 2022-07-01 エスティーブ ファーマシューティカルズ エス エイ がんにおけるシグマ受容体リガンドの使用
TW201806601A (zh) 2016-07-12 2018-03-01 以斯提夫博士實驗室股份有限公司 σ受體配體在皰疹後遺疼痛中的用途
WO2018059420A1 (zh) * 2016-09-27 2018-04-05 苏州科睿思制药有限公司 E52862盐酸盐晶型h及其制备方法
WO2019068771A1 (en) 2017-10-04 2019-04-11 Esteve Pharmaceuticals, S.A. USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS
WO2021087299A1 (en) 2019-10-31 2021-05-06 E-Scape Bio, Inc. Solid forms of an s1p-receptor modulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
AU2005276590B2 (en) 2004-08-27 2011-05-19 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1994032A1 (en) * 2006-03-01 2008-11-26 Laboratorios del Dr. Esteve S.A. Pyrazole derivatives as sigma receptor inhibitors
US7695199B2 (en) 2006-07-20 2010-04-13 Finisar Corporation Optical subassembly having insertable cylindrical sleeve
CN101328155B (zh) * 2007-06-20 2010-11-03 上海医药工业研究院 噁唑烷衍生物及其制备方法和应用
EP2113501A1 (en) 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors

Also Published As

Publication number Publication date
EP2531177B8 (en) 2016-10-12
TWI568729B (zh) 2017-02-01
KR20120123532A (ko) 2012-11-08
DK2531177T3 (en) 2016-08-22
MA34047B1 (fr) 2013-03-05
SMT201600264B (it) 2016-08-31
ES2586212T3 (es) 2016-10-13
IL221277A (en) 2017-06-29
TW201136923A (en) 2011-11-01
USRE47214E1 (en) 2019-01-29
EP2531177A1 (en) 2012-12-12
MX2012009018A (es) 2012-09-07
IL221277A0 (en) 2012-10-31
PH12012501510A1 (en) 2012-10-22
TN2012000347A1 (en) 2014-01-30
NZ601316A (en) 2013-12-20
SG182628A1 (en) 2012-08-30
WO2011095579A1 (en) 2011-08-11
JP5894086B2 (ja) 2016-03-23
CN102753155B (zh) 2015-11-25
BR112012018958A8 (pt) 2017-12-19
EP2531177B1 (en) 2016-05-11
SG10201500832PA (en) 2015-04-29
RU2012137495A (ru) 2014-03-10
MX339193B (es) 2016-05-16
CA2788024C (en) 2018-03-13
AU2011212476A1 (en) 2012-08-09
BR112012018958A2 (pt) 2016-04-12
RU2560150C2 (ru) 2015-08-20
RS55046B1 (sr) 2016-12-30
CA2788024A1 (en) 2011-08-11
PL2531177T3 (pl) 2016-11-30
JP2013518857A (ja) 2013-05-23
ECSP12012039A (es) 2012-08-31
AR080133A1 (es) 2012-03-14
US20120316336A1 (en) 2012-12-13
PT2531177T (pt) 2016-08-17
ME02483B (me) 2017-02-20
AU2011212476B2 (en) 2016-03-31
HRP20160937T1 (hr) 2016-10-07
CN102753155A (zh) 2012-10-24
HUE029738T2 (en) 2017-04-28
KR20180063379A (ko) 2018-06-11
US9051275B2 (en) 2015-06-09
SI2531177T1 (sl) 2016-10-28
CO6592093A2 (es) 2013-01-02

Similar Documents

Publication Publication Date Title
CY1117886T1 (el) Υδροχλωρικη 4-[2-[[5-μεθυλ-1-(2-ναφθαλενυλ)-1η-πυραζολ-3-υλ]οξυ]αιθυλ]μορφολινη και επιδιαλυτωματα
CY1122330T1 (el) Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης
CY1119974T1 (el) Στερεες μορφες 3-(5-αμινο-2-μεθυλ-4-οξο-4η-κιναζολιν-3-υλ)-πιπεριδινο-2,6-διονης και φαρμακευτικες συνθεσεις και χρησεις αυτης
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
EA201001205A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1116871T1 (el) Παραγωγα πυρρολοτριαζινονης ως αναστολεις των ρι3κ
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
NO20090628L (no) Pyridizinon derivativater
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CY1117962T1 (el) Υδροχλωρικο αλας 4-[2-[[5-μεθυλο-1-(2- ναφθαλενυλο)-1η- πυραζολ-3-υλ]οξυ]αιθυλο] μορφολινης
EA201170772A1 (ru) Органические соединения
CY1114669T1 (el) Υποκατεστημενα παραγωγα σουλφοναμιδιου
CY1111367T1 (el) Νεα παραγωγα της διοσμετινης, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1113409T1 (el) Αναστολεις ακτ και ρ70 s6 κινασης
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
CY1117288T1 (el) Παραγωγα 2-οξο-1-πυρρολιδινυλ ιμιδαζοθειαδιαζολης
EA201001855A1 (ru) Соединения, содержащие циклобутоксигруппу
CY1113551T1 (el) Υποκατεστημενες ενωσεις νικοτιναμιδιου και η χρησιμοποιηση τους σε φαρμακα
UY34166A (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201400444A1 (ru) Производные 2-оксопиперидинила